The results of this study have significant implications for advancing therapeutic strategies in the field, particularly given the superiority of the combined anti-PD-1 and anti-TIGIT blockade in the epithelioid mesothelioma animal model, compared to the clinical standard-of-care treatments such as cisplatin/pemetrexed chemotherapy [32] and anti-PD-1 and anti-CTLA-4 inhibition [6]. The gene discussed is TIGIT; the disease is malignant epithelioid mesothelioma.